Hamilton acts for Karo Pharma AB in connection with EQT’s recommended public tender offer on Karo Pharma. The offer amounts to in total approximately SEK 6 billion. Completion of the offer is conditional upon customary conditions and the acceptance period is expected to commence on or about 13 November 2018.
Karo Pharma is a Specialty Pharma company, which develops and markets products for pharmacies as well as directly to the healthcare sector. Karo Pharma is listed on Nasdaq Stockholm, Mid Cap.